Impact of Cytoreductive Nephrectomy on Immune Checkpoint Inhibitor Therapy: Treatment Outcomes of Immune Inhibitors Combination Therapies for Metastatic Renal Cell Carcinoma With Primary Kidney Tumors
IO+IO and IO+TKI demonstrated comparable efficacy with distinct profiles. Deferred CN may improve survival when performed within an optimal therapeutic window in selected patients, emphasizing the importance of treatment timing and response-adapted selection in the ICI era.
Authors
- Hiroaki Shimmura
- Hiroki Ishihara
- Kazuhiko Yoshida
- Hironori Fukuda
- Junpei Iizuka
- Yuki Nemoto
- Hiroshi Kobayashi
- Tsunenori Kondo
- Yasunobu Hashimoto
- Toshio Takagi
Institutions
- Jyoban Hospital of Tokiwa Foundation (JP)
- Tokyo Women's Medical University Adachi Medical Center (JP)
- Tokyo Women's Medical University (JP)
- Noguchi Hospital (JP)
- Saiseikai Ibaraki Hospital (JP)
Publication Details
- Journal
- International Journal of Urology
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1111/iju.70382
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Tokyo Women's Medical University